Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 18 | 2022 | 960 | 5.160 |
Why?
|
| Renin-Angiotensin System | 15 | 2021 | 179 | 4.610 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 99 | 3.500 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 103 | 3.500 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2020 | 132 | 2.360 |
Why?
|
| Premature Birth | 5 | 2022 | 66 | 2.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2021 | 135 | 2.210 |
Why?
|
| Fetal Growth Retardation | 3 | 2022 | 34 | 1.650 |
Why?
|
| Peptide Fragments | 6 | 2021 | 399 | 1.430 |
Why?
|
| Kidney | 5 | 2022 | 518 | 1.330 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 1128 | 1.310 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 92 | 1.270 |
Why?
|
| Adolescent | 16 | 2022 | 3568 | 1.200 |
Why?
|
| Humans | 47 | 2022 | 32114 | 1.140 |
Why?
|
| Infant, Premature | 4 | 2019 | 69 | 1.080 |
Why?
|
| Child | 11 | 2022 | 2442 | 1.030 |
Why?
|
| Angiotensin I | 5 | 2021 | 241 | 1.020 |
Why?
|
| Graft Rejection | 2 | 2017 | 238 | 0.990 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 122 | 0.990 |
Why?
|
| Pregnancy | 8 | 2022 | 997 | 0.960 |
Why?
|
| Blood Pressure | 6 | 2022 | 845 | 0.890 |
Why?
|
| Female | 25 | 2022 | 20015 | 0.830 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 4 | 0.830 |
Why?
|
| Infant, Very Low Birth Weight | 6 | 2019 | 49 | 0.830 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 66 | 0.800 |
Why?
|
| Male | 24 | 2022 | 19217 | 0.790 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 13 | 0.780 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 517 | 0.780 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 5 | 0.770 |
Why?
|
| Infant, Newborn | 9 | 2022 | 672 | 0.750 |
Why?
|
| Disease Progression | 2 | 2020 | 594 | 0.750 |
Why?
|
| Purpura, Schoenlein-Henoch | 1 | 2019 | 3 | 0.690 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 166 | 0.680 |
Why?
|
| Continental Population Groups | 2 | 2019 | 237 | 0.670 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 291 | 0.650 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 15 | 0.630 |
Why?
|
| Food Supply | 1 | 2019 | 67 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 85 | 0.630 |
Why?
|
| Fetus | 1 | 2019 | 86 | 0.630 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 85 | 0.620 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 148 | 0.610 |
Why?
|
| Health Status Disparities | 1 | 2019 | 131 | 0.610 |
Why?
|
| Child Behavior | 1 | 2017 | 27 | 0.600 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 1542 | 0.600 |
Why?
|
| Complement C4b | 1 | 2017 | 2 | 0.600 |
Why?
|
| Nutritional Status | 1 | 2017 | 75 | 0.580 |
Why?
|
| Child, Preschool | 5 | 2022 | 1270 | 0.550 |
Why?
|
| Overweight | 1 | 2018 | 280 | 0.540 |
Why?
|
| Dietary Supplements | 1 | 2017 | 185 | 0.540 |
Why?
|
| Creatinine | 3 | 2022 | 195 | 0.540 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 201 | 0.540 |
Why?
|
| Hyperpigmentation | 1 | 2016 | 17 | 0.530 |
Why?
|
| Erythema | 1 | 2016 | 26 | 0.520 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 26 | 0.520 |
Why?
|
| Hot Temperature | 1 | 2016 | 71 | 0.520 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2015 | 7 | 0.520 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 26 | 0.510 |
Why?
|
| Transplants | 1 | 2015 | 23 | 0.510 |
Why?
|
| Isoantibodies | 1 | 2015 | 12 | 0.510 |
Why?
|
| Donor Selection | 1 | 2015 | 33 | 0.500 |
Why?
|
| HLA Antigens | 1 | 2015 | 40 | 0.500 |
Why?
|
| Angiotensin II | 4 | 2021 | 244 | 0.480 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 352 | 0.460 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3510 | 0.440 |
Why?
|
| Pain | 1 | 2016 | 288 | 0.440 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2265 | 0.420 |
Why?
|
| Sex Factors | 3 | 2019 | 667 | 0.410 |
Why?
|
| Nephrology | 2 | 2022 | 33 | 0.400 |
Why?
|
| Electronic Health Records | 3 | 2022 | 162 | 0.400 |
Why?
|
| Virus Internalization | 2 | 2020 | 7 | 0.360 |
Why?
|
| Risk Factors | 6 | 2021 | 3880 | 0.350 |
Why?
|
| Obesity | 1 | 2017 | 1176 | 0.330 |
Why?
|
| Renin | 2 | 2021 | 109 | 0.320 |
Why?
|
| Case-Control Studies | 2 | 2022 | 898 | 0.310 |
Why?
|
| Renal Dialysis | 2 | 2018 | 282 | 0.250 |
Why?
|
| Body Mass Index | 2 | 2018 | 923 | 0.250 |
Why?
|
| Prospective Studies | 2 | 2022 | 2283 | 0.250 |
Why?
|
| Sodium | 2 | 2021 | 39 | 0.240 |
Why?
|
| Potassium | 2 | 2021 | 40 | 0.240 |
Why?
|
| Comorbidity | 3 | 2020 | 566 | 0.230 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 100 | 0.200 |
Why?
|
| Losartan | 1 | 2022 | 64 | 0.200 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 65 | 0.200 |
Why?
|
| Aldosterone | 1 | 2021 | 26 | 0.200 |
Why?
|
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2021 | 3 | 0.190 |
Why?
|
| Lung Injury | 1 | 2022 | 68 | 0.190 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 15 | 0.190 |
Why?
|
| Health Personnel | 1 | 2022 | 121 | 0.190 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 10 | 0.190 |
Why?
|
| Medical History Taking | 1 | 2020 | 37 | 0.190 |
Why?
|
| Receptors, Virus | 1 | 2020 | 14 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 153 | 0.180 |
Why?
|
| Electrolytes | 1 | 2020 | 11 | 0.180 |
Why?
|
| Data Collection | 1 | 2021 | 182 | 0.180 |
Why?
|
| Tunica Intima | 1 | 2020 | 57 | 0.180 |
Why?
|
| Pediatrics | 1 | 2022 | 155 | 0.180 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 33 | 0.180 |
Why?
|
| Prognosis | 3 | 2020 | 1497 | 0.170 |
Why?
|
| Rats, Inbred Lew | 1 | 2020 | 118 | 0.170 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 31 | 0.170 |
Why?
|
| Saliva | 1 | 2019 | 36 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2020 | 1429 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2020 | 75 | 0.170 |
Why?
|
| Vitamin D | 1 | 2021 | 184 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2021 | 548 | 0.170 |
Why?
|
| Hydrocortisone | 1 | 2019 | 57 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 21 | 0.170 |
Why?
|
| Linear Models | 2 | 2017 | 449 | 0.170 |
Why?
|
| Proteinuria | 1 | 2019 | 59 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 246 | 0.170 |
Why?
|
| Prenatal Care | 1 | 2019 | 51 | 0.160 |
Why?
|
| Family Characteristics | 1 | 2019 | 36 | 0.160 |
Why?
|
| Algorithms | 1 | 2022 | 495 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 684 | 0.160 |
Why?
|
| Physical Fitness | 1 | 2019 | 131 | 0.160 |
Why?
|
| Hospitalization | 4 | 2022 | 470 | 0.160 |
Why?
|
| Cardiovascular System | 1 | 2019 | 43 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3306 | 0.160 |
Why?
|
| Angiotensins | 1 | 2018 | 42 | 0.160 |
Why?
|
| Infant | 2 | 2022 | 1062 | 0.160 |
Why?
|
| Logistic Models | 2 | 2017 | 783 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 582 | 0.150 |
Why?
|
| Placenta | 1 | 2019 | 74 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2018 | 54 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 190 | 0.150 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 27 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 429 | 0.150 |
Why?
|
| Animals | 2 | 2020 | 7542 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 18 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 308 | 0.150 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 7 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 876 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2018 | 198 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2022 | 1817 | 0.140 |
Why?
|
| United States | 3 | 2022 | 3976 | 0.140 |
Why?
|
| Biopsy | 1 | 2017 | 259 | 0.140 |
Why?
|
| Gestational Age | 3 | 2022 | 121 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 288 | 0.140 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 14 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2018 | 379 | 0.130 |
Why?
|
| Rats | 1 | 2020 | 1596 | 0.130 |
Why?
|
| Complement Pathway, Classical | 1 | 2015 | 2 | 0.130 |
Why?
|
| Complement C1q | 1 | 2015 | 4 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 770 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2019 | 682 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 185 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 458 | 0.120 |
Why?
|
| Young Adult | 1 | 2022 | 2665 | 0.120 |
Why?
|
| Exercise | 1 | 2019 | 673 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2015 | 198 | 0.110 |
Why?
|
| North Carolina | 1 | 2018 | 1538 | 0.110 |
Why?
|
| Graft Survival | 1 | 2015 | 313 | 0.110 |
Why?
|
| Adult | 2 | 2022 | 9380 | 0.100 |
Why?
|
| Brain | 1 | 2019 | 951 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 543 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 33 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 753 | 0.090 |
Why?
|
| Birth Weight | 2 | 2019 | 47 | 0.080 |
Why?
|
| Exercise Test | 2 | 2019 | 227 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 877 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 1199 | 0.070 |
Why?
|
| Privacy | 1 | 2022 | 10 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 28 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 46 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 100 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 39 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2022 | 483 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2021 | 9 | 0.050 |
Why?
|
| Chromatography, Agarose | 1 | 2021 | 5 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2021 | 25 | 0.050 |
Why?
|
| Reference Standards | 1 | 2021 | 32 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 188 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2021 | 33 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 142 | 0.050 |
Why?
|
| China | 1 | 2020 | 50 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2022 | 525 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 14 | 0.050 |
Why?
|
| Veterans | 1 | 2021 | 68 | 0.050 |
Why?
|
| Chlorides | 1 | 2020 | 13 | 0.050 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 16 | 0.050 |
Why?
|
| Publishing | 1 | 2021 | 60 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 61 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 107 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 189 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 108 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 85 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 765 | 0.040 |
Why?
|
| Lung | 1 | 2020 | 249 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 1 | 2018 | 9 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 315 | 0.040 |
Why?
|
| Calcium | 1 | 2020 | 307 | 0.040 |
Why?
|
| Aged | 2 | 2022 | 10314 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 33 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 408 | 0.040 |
Why?
|
| Uric Acid | 1 | 2017 | 27 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 989 | 0.040 |
Why?
|
| Middle Aged | 2 | 2022 | 11839 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 881 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 355 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1189 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 238 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 472 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 252 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 397 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1166 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1425 | 0.030 |
Why?
|